Pharmafile Logo
Pharmafocus logo
Advanced Search

Tasigna

Showing 11 posts of 11 posts found.

Novartis’s Tasigna scores EU approval in paediatric patients

November 20, 2017
Sales and Marketing Europe, Novartis, Tasigna, chronic myeloid leukaemia, pharma

Novartis’s Tasigna (nilotinib) has received European Commission approval for the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in …

News

NICE says yes to Tasigna for resistant disease

January 13, 2012
Sales and Marketing BMS, Glivec, NICE, Novartis, Tasigna

NICE is recommending Novartis’ Tasigna for chronic myeloid leukaemia patients that can no longer use Glivec. In final guidance it …

News
Glivec picture

NICE recommends two Novartis cancer treatments

December 6, 2011
Sales and Marketing Glivec, Novartis, Sprycel, Tasigna

Two of Novartis’ cancer drugs have been recommended by NICE for the first line treatment of chronic myeloid leukaemia (CML) …

News
Novartis

New discount persuades NICE to back Novartis’ Tasigna

August 18, 2011
Sales and Marketing Glivec, NICE, Sprycel, Tasigna

NICE has recommended Novartis’ Tasigna for use in the NHS after the blood cancer drug’s manufacturer submitted a new patient …

News

‘Weak’ evidence leads to NICE no for three leukaemia drugs

May 6, 2011
Sales and Marketing Glivec, NICE, Sprycel, Tasigna

NICE has not recommended three major drugs for the rare blood cancer chronic myeloid leukaemia. In draft guidance on treating …

News

Novartis ends phase III trial of Tasigna

April 12, 2011
GIST, Glivec, Novartis, Tasigna

Novartis has stopped a late stage study of Tasigna for certain types of stomach cancers after it failed to show …

News
Advanced melanoma

Melanoma: intense competition to be the next milestone treatment

February 9, 2011
Research and Development BRAF V600 mutation, Cancer, Tasigna, cancer research, melanoma, tremelimumab

A flurry of new data has emerged in the recent months from an industry-wide pipeline of cancer drugs which could …

Feature

Swiss approval for Novartis’ Tasigna

August 31, 2010
Sales and Marketing Novartis, Tasigna, Tekamlo

Novartis’ Tasigna has received its first European approval as a first-line treatment after Swiss authorities green-lighted the blood cancer drug …

News
Novartis Tasigna website

Digital Pharma: Novartis rapped for Facebook sharing

August 10, 2010
Medical Communications Digital Pharma blog, Facebook, Novartis, Tasigna

Novartis has had its knuckles rapped by the FDA over the company’s use of social media sharing tools. At issue …

News

New products spur Novartis growth

July 15, 2010
Sales and Marketing Novartis, Tasigna

Novartis has posted strong results for the second quarter of the year. The Swiss pharma company posted an 11% rise …

News

Tasigna more effective than Glivec, says Novartis

June 21, 2010
Research and Development, Sales and Marketing Glivec, Novartis, Tasigna, leukaemia

Novartis has gained US approval for Tasigna to be used as a front line treatment for chronic myeloid leukaemia. The …

News

Latest content

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024